胃癌109例雌激素受体与孕激素受体的检测研究  

Estrogen and Progesterone Receptors in Gastric Cancer

作　　者：石晓毅[1] 沈明[1] 江萍 王玲娟[1] 

机构地区：[1]北京铁路总医院肿瘤研究所

出　　处：《中国肿瘤临床》1995年第5期348-350,共3页Chinese Journal of Clinical Oncology

摘　　要：自１９８６～１９９３年采用李氏荧光雌激素组织化学法对胃癌１０９创作了雌激素受体（ＥＲ）、孕激素受体（ＰｇＲ）测定，同时对８例非肿瘤病人的胃正常粘膜作了ＥＲ、ＰｇＲ测定。１０９例胃癌的ＥＲ、ＰｇＲ阳性率分别为２３％、２７．５％，８例非肿瘤病人的胃正常粘膜ＥＲ、ＰｇＲ均阴性。１０９例胃癌中高分化腺癌ＥＲ、ＰｇＲ阳性率分别为４４．１％（１５／３４）、４７．１％（１６／３４），均明显高于低分化腺癌的１４％（６／４３）及２０．９％（９／４３），ＥＲ为Ｐ＜０．０２、ＰｇＲ为Ｐ＜０．０５，发病年龄及性别与ＥＲ、ＰｇＲ均无关。认为ＥＲ、ＰｇＲ阳性的胃癌与雌激素靶器官的恶性肿瘤一样，可能为雌激素依赖性肿瘤，对内分泌治疗有着良好的前景。The presence of estrogen and progesterone receptors (ER, PgR) was observed in 109 gastric cancer tissues, and 8 normal gastric mucosa tissues as control. The results showed that the positive rates of ER and PgR in gastric cancer were 23.0% and 27. 5%, whereas they were all negative in the control group. The positive rates of ER and PgR in highly differentiated adenocarcinomas were 44. 1% and 47. 1%, while in lowly differentiated adenocarcinomas they were 14.0% and 20. 9%. It is indicated that positive rates of ER and PgR are not related to age or sex. These findings suggest that the growth of a fraction of gastric carcinoma may be estrogen dependent and that anti-estrogen treatment may offer a new approach in gastric cancer treatment.

关 键 词：胃肿瘤 癌 雌激素 孕激素 受体 诊断 

分 类 号：R735.204[医药卫生—肿瘤]